Purified extract (ATC1) isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma

Patent metadata

Field	Value
Publication number	US-10046019-B2
Application number	US-201615261998-A
Country	US
Kind code	B2
Filing date	Sep 11, 2016
Priority date	Dec 31, 2012
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

First claim

The invention claimed is:

1. A purified extract fractionated with butanol (ATC1) from the extract of Pseudolysimachion rotundum var subintegrum , comprising 15%-50% (w/w) verproside, 0.3%-10% (w/w) veratric acid, 0.5%-10% (w/w) catalposide, 0.3%-10% (w/w) picroside II, 0.3%-10% (w/w) isovanilloyl catalpol and 0.5%-10% (w/w) 6-O-veratroyl catalpol based on the weight of total extract (100%) of Pseudolysimachion rotundum var subintegrum , being prepared by the process of; adding the mixture of water and ethanol to dried Pseudolysimachion rotundum var subintegrum at the 1st step; subjecting to at least one extraction method selected from reflux extraction with hot water, cold water extraction, ultra-sonication or conventional extraction, followed by reflux extraction at the temperature ranging from 10° C. to 100° C., for the period ranging from 30 mins to 72 hours, repeatedly, to afford the 1st extract at 2nd step; suspending the 1st extract in 0.5-10 fold volume (v/v) of water to afford suspended extract at 3rd step; and adding about 0.5-20 fold volume (v/v) of butanol, fractionating into water layer and butanol layer and collecting the butanol layer to afford the purified extract fractionated with butanol (ATC1).

2. A pharmaceutical composition comprising the purified extract fractionated with butanol (ATC1) as set forth in claim 1 ; isolated from Pseudolysimachion rotundum var subintegrum as an active ingredient and a pharmaceutically acceptable carrier or excipient.

3. A health functional food comprising the purified extract fractionated with butanol (ATC1) as set forth in claim 1 ; isolated from Pseudolysimachion rotundum var subintegrum.

4. A purified extract fractionated with butanol (ATC1) from the extract of Pseudolysimachion rotundum var subintegrum , comprising 12.3%-47% (w/w) catalpol derivatives selected from the group consisting of verproside, catalposide, picroside II, isovanilloyl catalpol and 6-O-veratroyl catalpol in total extract (100%) of Pseudolysimachion rotundum var subintegrum and which has a relative mixed ratio (w/w) between the weight of each catalpol derivative of 15.0-18.0 (w/w) verproside, 2.10-2.60 (w/w) catalposide, 1 (w/w) picroside II, 1.00-1.30 (w/w) isovanilloyl catalpol and 2.00-2.30 (w/w) 6-O-veratroyl catalpol being prepared by the process of; adding the mixture of water and ethanol to dried Pseudolysimachion rotundum var subintegrum at the 1st step; subjecting to at least one extraction method selected from reflux extraction with hot water, cold water extraction, ultra-sonication or conventional extraction, followed by reflux extraction at the temperature ranging from 10° C. to 100° C., for the period ranging from 30 mins to 72 hours, repeatedly, to afford the 1st extract at 2nd step; suspending the 1st extract in 0.5-10 fold volume (v/v) of water to afford suspended extract at 3rd step; and adding about 0.5-20 fold volume (v/v) of butanol, fractionating into water layer and butanol layer and collecting the butanol layer to afford the purified extract fractionated with butanol (ATC1).

5. A pharmaceutical composition comprising the purified extract fractionated with butanol (ATC1) as set forth in claim 4 ; isolated from Pseudolysimachion rotundum var subintegrum as an active ingredient and a pharmaceutically acceptable carrier or excipient.

6. A health functional food comprising the purified extract fractionated with butanol (ATC1) as set forth in claim 4 ; isolated from Pseudolysimachion rotundum var subintegrum.

Assignees

• Yungjin Pharmaceutical Co Ltd
• Korea Res Inst Bioscience & Biotechnology

Inventors

• Lee Yongnam
• Yoo Ji-Seok
• Shin Dae-Hee
• Ryoo Byung-Hwan
• Oh Sei-Ryang
• Ahn Kyung-Seop
• Lee Hyeongkyu
• Kwon Ok-Kyoung
• Kim Doo-Young
• Kim Jung-Hee
• Song Hyuk-Hwan

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title